X-XSS-Protection: 1; mode=block X-Content-Type-Options: nosniff Strict-Transport-Security: max-age=63072000; includeSubDomains; preload

About Us

Strong industrial and scientific leadership

Founded in 2014, Edinburgh Molecular Imaging is a clinical phase biotechnology company focused on enabling image guided interventional medicine. The company’s molecular targetting technology has the potential to tackle disease in real-time to allow interventional procedures including surgery and therapy, providing more accurate treatment while sparing healthy tissue.

The focus of EM Imaging is the discovery and development of small molecules and peptides that, when conjugated with fluorescent dyes or radionuclides, target and specifically bind with cancerous cells and other diseased tissues. This provides the clinician with a clearer view of the extent of disease and thus a decision-making tool to benefit the patient.
The EM Imaging team has decades of documented success in imaging agent amd therapeutics discovery and development, with expertise spanning from medicinal chemistry, radiochemistry, biochemistry and cell biology, along with direct clinical expertise. The team also has significant expertise in the clinical development, approval and reimbursement of molecular imaging and therapeutic agents. EM Imaging plans to become a leader in offering targeted fluorescent optical imaging and therapy agents as a cost effective and accessible imaging modality.

Management Team

Roy Davis

Roy Davis

Chairman

Mr Davis is currently Chairman of Medica Group plc (the UK’s leading tele-radiology company).

He was formerly CEO of Optos Plc, a leading retinal imaging manufacturer from 2008 to 2015 until its sale to Nikon for $400 million in 2014; he continues to be an advisor to Nikon. Prior to this, Mr Davis was CEO of Gyrus Group plc, a leading medical device company focused on minimally invasive surgery and visualisation until it was acquired by Olympus in 2008 for approximately $2 billion.

Mr Davis has over 30 years of operational expertise and strategic consulting experience and holds a mechanical engineering degree, with honours, from Southampton University and an MBA from the London Business School.

Bernhard Sixt

Bernhard Sixt

CEO

Dr Sixt has 30 years of healthcare industry experience in the development and commercialisation of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham (now part of GE Healthcare) and Nycomed Pharma (now part of Takeda).

Since leaving Amersham, Bernhard has led several companies. He is a co‑founder of Agendia and served as its CEO from 2003 until 2011 and in 2005 founded Ipotuba, a pioneer for addressing the emerging need for pharmaceutical cryo-logistics. He also led ImmunID, an innovator in precision immuno-oncology, from 2013 until 2016.

Dr Sixt holds a Master of Science degree in Biochemistry and Chemistry from Ludwig Maximilians University (LMU) and a PhD from the Technical University (TU), both in Munich, Germany

Barry Knight

Barry Knight

CFO

Mr Knight has more than 25 years’ experience as an executive director in life sciences businesses.

Before joining EM Imaging he was COO at Kinapse Ltd, an international consulting and outsourcing business servicing the world’s top pharmaceutical companies and Finance Director of Fulcrum Pharma plc, an AIM listed international consultancy. 

Prior to joining Fulcrum Pharma, Barry was Finance and Administration Director in rapidly growing biotechnology and medical device companies.

Elizabeth Roper

Elizabeth Roper

Director

Dr. Roper has more than 15 years experience in the Life Science and Healthcare industry, primarily in venture capital fund management and industry Dr. Roper was involved in many key company strategic decisions and successfully established a number of major company-building alliances. She is a former executive with the Life Science venture capital team at the Investments Division of The Wellcome Trust.  In this role, Dr. Roper provided direct early-stage equity financing to private companies in the Life Sciences industry in the US and Europe.  Her investments included Fovea Pharmaceuticals, Nabriva Therapeutics and Sirtris Pharmaceuticals.

She is also a former member of the Life Science team at Atlas Ventures, London.  Dr. Roper holds a B.Sc. (Hons) in Biochemistry (1st class) from the University College Cork, and a Ph.D. from the Imperial Cancer Research Fund.

Daniel Marshall

Daniel Marshall

Director

Dr. Marshall has more than eight years’ experience in early stage business development and venture.

Prior to his time at IP Group, Daniel worked in both the business development and due diligence teams at LifeArc (formerly MRC Technology). Working closely with the LifeArc drug discovery and development teams, Daniel has broad experience of the development and commercialization of pre-clinical drug discovery programs. While at LifeArc Daniel, also ran the dementia consortium, a small fund to de-risk novel neurodegeneration targets in partnership with several pharmaceutical companies.

Dr. Marshall has a Ph.D. in Immunology from National Institute for Medical Research, University College London and spent time working in the in vivo pharmacology team at Envigo.